After moving 0.7% during today's evening session, Regeneron Pharmaceuticals is now trading at a price of $830.69 per share. On average, analysts give it a target price of $898.86.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Potential Regeneron Pharmaceuticals Investors Should Analyze the Following:
-
Regeneron Pharmaceuticals has moved 15.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 4.2. A number between 0 and 1 could mean that the market is undervaluing Regeneron Pharmaceuticals's estimated growth potential
-
Its Price to Book (P/B) ratio is 3.68
Understanding Regeneron Pharmaceuticals's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-06 | 12,172,900 | -5,618,500 | 41 | -26.79 |
| 2022-02-07 | 16,071,700 | -4,639,400 | 56 | 30.23 |
| 2021-02-08 | 8,497,100 | -3,712,600 | 43 | 26.47 |
| 2020-02-07 | 6,557,600 | -3,582,700 | 34 | -30.61 |
| 2019-02-07 | 5,145,600 | -2,193,700 | 49 | 40.0 |
| 2018-02-08 | 5,872,200 | -3,395,500 | 35 |
Regeneron Pharmaceuticals's operating margins have averaged 43.0% over the last 6 years, which is significantly higher than the Pharmaceutical industry average of 12.02%. The firm's margins exhibit a relatively stable growth trend of 2.7%.
